EP3749095A1 - Antibakterielles und spermizides gleitmittel - Google Patents
Antibakterielles und spermizides gleitmittelInfo
- Publication number
- EP3749095A1 EP3749095A1 EP19702647.9A EP19702647A EP3749095A1 EP 3749095 A1 EP3749095 A1 EP 3749095A1 EP 19702647 A EP19702647 A EP 19702647A EP 3749095 A1 EP3749095 A1 EP 3749095A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- guanidine
- composition according
- composition
- polymeric
- biocide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims description 6
- 239000000314 lubricant Substances 0.000 title description 13
- 230000001150 spermicidal effect Effects 0.000 title description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims abstract description 104
- 239000000203 mixture Substances 0.000 claims abstract description 101
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims abstract description 51
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims abstract description 51
- 239000003139 biocide Substances 0.000 claims abstract description 37
- 230000003115 biocidal effect Effects 0.000 claims abstract description 36
- 239000000126 substance Substances 0.000 claims abstract description 23
- 239000002562 thickening agent Substances 0.000 claims abstract description 19
- 239000000934 spermatocidal agent Substances 0.000 claims abstract description 18
- 239000007864 aqueous solution Substances 0.000 claims abstract description 7
- 230000001568 sexual effect Effects 0.000 claims description 24
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 21
- -1 Poly (hexamethylene guanidine Chemical compound 0.000 claims description 14
- 229920001223 polyethylene glycol Polymers 0.000 claims description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 claims description 11
- 239000003589 local anesthetic agent Substances 0.000 claims description 10
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 9
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 9
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 239000000829 suppository Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 229940087419 nonoxynol-9 Drugs 0.000 claims description 6
- 229920004918 nonoxynol-9 Polymers 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 6
- 230000000840 anti-viral effect Effects 0.000 claims description 5
- 239000003906 humectant Substances 0.000 claims description 5
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 208000019802 Sexually transmitted disease Diseases 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 239000003349 gelling agent Substances 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 230000000843 anti-fungal effect Effects 0.000 claims description 3
- 229940121375 antifungal agent Drugs 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 150000004820 halides Chemical class 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 229920001281 polyalkylene Polymers 0.000 claims description 3
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 claims description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 2
- 239000012876 carrier material Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 claims description 2
- 229940050410 gluconate Drugs 0.000 claims description 2
- 229940116364 hard fat Drugs 0.000 claims description 2
- 229940075554 sorbate Drugs 0.000 claims description 2
- 239000001828 Gelatine Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 description 45
- 229960004198 guanidine Drugs 0.000 description 38
- 230000000694 effects Effects 0.000 description 25
- 238000009472 formulation Methods 0.000 description 22
- 239000000499 gel Substances 0.000 description 19
- 150000002357 guanidines Chemical class 0.000 description 18
- 230000005540 biological transmission Effects 0.000 description 14
- 229950003169 nonoxinol Drugs 0.000 description 14
- KUXGUCNZFCVULO-UHFFFAOYSA-N 2-(4-nonylphenoxy)ethanol Chemical compound CCCCCCCCCC1=CC=C(OCCO)C=C1 KUXGUCNZFCVULO-UHFFFAOYSA-N 0.000 description 13
- 239000002202 Polyethylene glycol Substances 0.000 description 12
- 229920000642 polymer Polymers 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 244000052769 pathogen Species 0.000 description 9
- 229920000136 polysorbate Polymers 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 229950008882 polysorbate Drugs 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 241000222122 Candida albicans Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 241001225321 Aspergillus fumigatus Species 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 4
- 241000235645 Pichia kudriavzevii Species 0.000 description 4
- 125000005263 alkylenediamine group Chemical group 0.000 description 4
- 229940091771 aspergillus fumigatus Drugs 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000004985 diamines Chemical class 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 3
- 229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 description 3
- 229960004194 lidocaine Drugs 0.000 description 3
- 238000001728 nano-filtration Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002413 Polyhexanide Polymers 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 206010041925 Staphylococcal infections Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000002254 contraceptive effect Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000000423 heterosexual effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 206010036596 premature ejaculation Diseases 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- CGTDZIUMWOTEHH-UHFFFAOYSA-N 2-[2-(2-ethoxyethoxy)ethyl]guanidine Chemical compound CCOCCOCCNC(N)=N CGTDZIUMWOTEHH-UHFFFAOYSA-N 0.000 description 1
- VYMFQAYLNYQHER-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VYMFQAYLNYQHER-UHFFFAOYSA-N 0.000 description 1
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- HLKHRRVTJUCBFZ-UHFFFAOYSA-N carbamimidoyl-[2-(2-ethoxyethoxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOCCOCC[NH2+]C(N)=N HLKHRRVTJUCBFZ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000001614 effect on membrane Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 230000000652 homosexual effect Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 229940098514 octoxynol-9 Drugs 0.000 description 1
- 229920002114 octoxynol-9 Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000005702 oxyalkylene group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 238000006068 polycondensation reaction Methods 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000004999 sex organ Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
- A01N47/40—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides
- A01N47/42—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides containing —N=CX2 groups, e.g. isothiourea
- A01N47/44—Guanidine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
- A01N31/02—Acyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates to an intimate use with a spermicide in a stable gel formulation.
- nonionic compounds ostensibly polyethylene glycol (PEG) or polysorbate (Tween). High amounts of such compounds
- Solubilizer v.a. of PEG are essential, since otherwise the spermicide precipitates and milky pastes arise. PEG and polysorbate are harmful substances as they lower the barrier function of the skin. This is especially true for one
- Alkylphenoxypolyethoxyethanols in particular nonoxynol-9, are themselves strong surface-active substances (US Pat. No. 6,028,115) and it is therefore detrimental for their effect if microphase separations, such as emulsions, form in a formulation since microheterogeneities are formed in the formulation, which zones differ, inclusive severely weakened, activities, form.
- WO 2008/031105 A1 describes polymeric guanidine germicides for topical skin treatment of animals.
- UA 64 406 A (abstract) describes an ointment with Polyhexamethylene guanidine phosphate and various oils for the treatment of ulcerated necrotic gingivostomatitis.
- polyethoxylated nonionic compounds can be omitted if the formulation of the antimicrobial agent from the group of polymeric guanidines is added in small quantities.
- the invention therefore relates to a chemical composition containing at least one polymeric guanidine biocide and
- At least one alkylphenoxypolyethoxyethanol spermicide in aqueous solution, and at least one thickening agent.
- composition allows the suppression of
- Gel formulation offers the advantage of a lubricant gel to enable a pain-free and friction-reduced sexual intercourse. As a result, they fail during a
- composition of the invention the biocidal effect of
- Disinfectants known. Their preparation is described in WO 01/85676 A1 and in patents AT 408302 B and AT 411060 B. Polymeric guanidine biocides are also called Akacid, or X-Cid, and are described in Kratzer et al. , Antibiotics
- the polymeric guanine biocide can also be present as a complex, for example with gelatin or a polysaccharide (for example as in WO
- WO 2008/080184 describes the use of polymeric guanidines for controlling
- Microorganisms in non-therapeutic applications e.g. by nebulization for room disinfection.
- Composition thereof is Akacid, poly [2- (2-ethoxy) -ethoxy-ethyl-guanidinium chloride and Akacid plus, a 3: 1 mixture of poly (hexamethyleneguanidinium chloride) and poly [2- (2-ethoxy) ethoxyethyl] guanidinium chloride].
- polymeric guanidines is used in particular for “polymeric guanidine derivatives based on an alkylenediamine and / or an oxyalkylenediamine” (WO 2009/009815 A1), especially for “biocidal polymeric guanidine derivatives based on
- Diamines containing alkyl chains or oxyalkylene chains between two amino groups said guanidine derivatives using a product of the polycondensation of a guanidine acid addition salt with diamines containing polyalkylene chains or polyoxyalkylene chains between two amino groups "(EP 1 280 766 B1, claim 1) preferred are a
- Poly (hexamethyleneguanidinium) salt and / or poly [2- (2-ethoxy) ethoxyethyl] guanidinium salt are preferred polymeric guanidine biocides according to the present invention.
- Composition is characterized in that a polymeric guanidine biocide is provided which contains an alkylenediamine and the oxyalkylenediamine in the molar ratio between 4: 1 and 1: 4.
- Oxyalkylenediamines are preferably terminal, wherein the
- Preparation of the polymeric guanidine biocide as alkylene diamine is provided primarily a compound of the general formula NH 2 (CH 2 ) n NH 2 , in which an integer between 2 and 10, in particular 6, is.
- a compound of the general formula NH 2 (CH 2 ) n NH 2 in which an integer between 2 and 10, in particular 6, is.
- Preferred polymeric guanidine biocides may be selected from poly (hexamethylene guanidine; poly [2- (2-ethoxy) ethoxyethyl] guanidine; Polytriethylenglykolguanidin; Polyethylenglykolguanidin; Polyoxypropylenguanidin;
- the polymeric guanidine biocide is a polyalkylene guanidine, especially a polyoxyalkylene guanidine.
- Alkylene may be a C1-C8 alkyl, preferably a C2-C6 alkyl such as ethyl, propyl, butyl, methylpropyl, pentyl, branched or unbranched, which is preferred in all uses of the term “alkylene” or "alkyl” herein.
- polyguanidine can be of the formula (I), (II)
- R 2 is either an aromatic ring system having at least one aromatic ring optionally containing one or more heteroatoms selected from O, N and S, and
- RI is benzene (preferably para- or meta-digested), pyridine (preferably the two
- Polymeric guanidines may also contain the formula (IV)
- X is selected from -NH 2 , aminoguanidino and 1, 3-diaminoguanidino;
- Y is selected from -H and -R I -NH 2 ; or X and Y together represent a chemical bond to give a cyclic structure;
- a and b are each 0 or 1
- R 2 is selected from -H and -NH 2 ,
- polypeylan guanidines are in WO 2014/113835 Al described.
- n a plurality, e.g. to achieve the above molar masses of the polymer.
- n can be 3 to 200.
- polymeric guanidines of the examples of WO 2014/113835 A1 and WO 2016/015081 A1 are particularly preferred
- PMAG Polymetaxylidenaminoguanidine
- polymeric guanidines of WO 2014/113835 A1 and WO 2016/015081 A1 have the advantages that they can be prepared with low residual monomers (such as the otherwise frequently occurring HMDA-hexamethylenediamine) and therefore have low toxicity, which is a particular advantage according to the invention.
- Particularly preferred is a
- composition of gelling agent (or another)
- PMAG (or another polymeric guanidine, in particular the WO
- the guanidine is a guanidinium salt
- halide preferably a chloride
- Phosphate preferably a dihydrogen phosphate
- the polymeric guanidine of the invention may be
- Salting partners (counterions), e.g. Halide, phosphate, etc. are described in AT 411060 B.
- the average molecular weight of the polymeric guanidine biocide is 200 Da to 10,000 Da, preferably 500 Da to 3000 Da.
- the polymeric guanidine biocide may be provided with at least 3 guanidine residues.
- the polymers of these sizes can be obtained by nanofiltration through membranes. For nanofiltration, filters with corresponding pore sizes can be used for the permeability of the desired molecular weights.
- Filtrates to remove larger polymers
- the residue to remove the smaller polymers
- polymeric guanidine biocides have improved toxicology.
- the elimination of short-chain oligomers and monomers, as well as the elimination of the entrained by the synthesis residues of the diamines is a major focus. These could otherwise be from the
- Vaginal mucosa resulting in undesirable pharmacological effects.
- the main focus of the formulation is on the local application and trivalent effect without undesirable effects. Accordingly, monomeric starting materials (guanidines) and oligomers or polymers of guanidine biocide having a molecular weight of 250 Da or less, or even 400 Da or smaller, are removed.
- the content of monomers and short-chain oligomers of guanidine having a molecular weight of 250 Da or smaller, such as HMDA, is preferably less than 0.1% by weight of
- Composition more preferably below 0.05%
- composition especially preferably less than 0.01%, less than 0.005%, less than 0.001% or even less than 0.0001% of the composition (all% in% by weight).
- the composition is free thereof or has been removed as described above, e.g. by nanofiltration.
- the polymeric guanidine biocide is provided in an amount or concentration sufficient to inhibit the growth of pathogenic bacteria (gam negative and / or gram positive) in the human body
- Such bacteria which are inhibited according to the invention are e.g. S. aureus, E. coli, P. aeruginosa.
- the polymeric guanidine may be biocide in a sufficient amount or concentration
- Such fungi which are inhibited according to the invention are e.g. C. albicans, S.
- the polymeric guanidine may be biocide in a sufficient amount or concentration
- composition of the invention may further comprise
- Nonylphenoxpoly (ethyleneoxy) ethanol (nonoxynol-9).
- This is particularly preferred for use as a "liquid condom", ie as a liquid, fluid or fluidizable (hence “liquid”) means of contraception in addition to reducing disease transmission.
- Preferred spermicides which can be used according to the invention are nonoxynol-9, octoxynol-9, dodecaethylene glycol monolaurate, laureth 10S and methoxypolyoxyethylene glycol 550 laurate.
- spermicide For special use, namely the use of homosexuals, this spermicide is not needed. Instead, a local anesthetic, such as lidocaine, is used for a premature climax during intercourse,
- Local anesthetics may preferably be benzocaine, dibucaine,
- Diphenylhydramine hydrochloride and the like are not limited thereto.
- Alkylphenoxypolyethoxyethanol spermicides such as nonoxynol-9 are known and e.g. described in US 5,512,289. As mentioned in the introduction, the combination of a
- Alkylphenoxypolyethoxyethanol spermicides with an aqueous polymeric gel matrix are solution problems, US 5,512,289 proposing to use surface-active substances such as polysorbate or high PEG amounts. According to the invention can on this
- composition suitable for sexual intercourse Both substances (the polymeric guanidine biocide and the Alkylphenoxypolyethoxyethanol) according to the invention are present in solutions or are soluble, completely without
- composition according to the invention is in particular a lubricant or lubricant for sexual intercourse.
- Viscosity which is achieved by a thickener.
- the viscosity may be 1 Pas or more, more preferably 1 Pas to 900 Pas, especially preferably 7 Pas to 500 Pas,
- the viscosity is determined at 36 ° C and atmospheric pressure (lbar).
- the thickener is a gelling agent. It can e.g. be selected from hydroxyalkylcellulose, cellulose, hydroxyethylcellulose, hydroxypropylcellulose,
- the thickening agent in suppositories may be a suppository carrier material, preferably
- Hard fat (Adeps neutralis), a glycerol gelatin mixture or soluble PEG, e.g. PEG 400/4000, wherein PEG is less preferred or is not in the composition according to the invention due to the effect on membranes and the increase of their permeability.
- the thickener may also have film-forming properties. Associated or independent of the thickener, the composition may also preferably include one or more film-forming polymers, gums, chitosans, or the like
- celluloses e.g. derived from water-soluble celluloses.
- such are derived from cellulose
- hydroxyalkylcellulose polymers More preferably, the hydroxyalkyl cellulose polymer is selected from the following
- hydroxyalkyl cellulose polymer is hydroxypropyl cellulose.
- Alkyl may be defined as above for the polymer (C1-C8 alkylene, incl. Preferred
- the composition preferably contains from 0.05% to 1% by weight of polymeric guanidine biocide, more preferably from 0.1% to 2%, even more preferably from 0.4% to 3% (all wt%).
- the composition preferably contains 0.05% to 8% (wt.%) Alkylphenoxypolyethoxyethanol spermicid, especially preferred 0.1% to 6%, especially preferred 0.3% to 2% (all wt%).
- the composition preferably contains 1% to 95% (wt.%) Thickener.
- the composition preferably contains 1% to 30%
- Thickener which may be a gelling agent.
- the range is 1.5% to 20%, more preferably 2% to 6% (all wt%).
- all wt% is the amount
- Thickening agent preferably 50% to 95%, in particular
- composition may be provided in a single-dose form, e.g. in an amount of 1ml to 10ml,
- a single-use dosage form is e.g. a disposable pipette.
- a disposable pipette can be a
- composition may further contain a humectant, e.g. Propylene glycol or glycerin.
- a humectant e.g. Propylene glycol or glycerin.
- Humectant can be provided in a concentration of 1% to 30%, preferably 3% to 18% (all wt .-%),
- the composition is a homogeneous one
- Composition (no different phases) which can be administered vaginally as such.
- it does not require solid supports, such as a sponge, and is used without such a solid support which remains solid in use (as opposed to the suppository).
- composition may further include acidulants such as Acidum citricum or with additional antioxidant activity, such as
- the composition has a pH in the range of 4.5 to 8. More preferably, from 5 to 7.
- the pH can be adjusted by conventional acids and bases and is
- an acid or base should be a weak acid or base.
- Preferred pasture are acids
- PEG Polyethylene glycol
- Tween polysorbate
- small or insignificant amounts of these undesirable substances may be present, e.g. a maximum of 1% or a maximum of 0.5% (all wt .-%).
- oxidizing substances such as povidone iodine, these are either completely avoided or are present only in small amounts, e.g. maximum 0.5% or maximum 0.1% (all wt .-%).
- surfactants such as benzalkonium chloride are undesirable substances because they can increase the permeability of the vaginal mucosa to pathogens. These substances are preferably at most 1%, especially
- the active compounds of the invention such as the polymeric guanidine biocide or the spermicide or the local anesthetic are not counted among the undesirable substances.
- composition may also include pharmaceutical carriers, binders, preferably polymeric binders and / or
- carrier refers to a diluent, e.g. Water, saline, binding agent or medium with which the composition can be administered.
- a diluent e.g. Water, saline, binding agent or medium with which the composition can be administered.
- microcrystalline cellulose microcrystalline cellulose, polyvinylpyrrolidone (polyvidone or povidone), gum tragacanth, gelatin, starch, lactose or
- Lactose monohydrate Lactose monohydrate, alginic acid, corn starch and the like
- a lubricant or surfactant such as magnesium stearate or sodium lauryl sulfate
- a flow control agent such as colloidal silica
- Invention contains the following:
- polymeric guanidine biocide 0.05% to 10%
- Humectants 5% to 15%, Alkylphenoxypolyethoxyethanol spermicide: 0, 05% to 10%, thickener: 1% to 10%, all% in% by weight.
- composition may further contain:
- Acidum Ascorbicum and / or Acidum Citricum 0% to 3%
- Citric acid 0% to 4%
- composition may also contain other buffer components
- the present invention further relates to a use of the composition according to the invention according to any embodiment for vaginal antibacterial, antifungal and / or antiviral disinfection. Likewise, the invention relates to the use thereof as a lubricant during a
- Nonoxinol is optional (e.g., as a pure lubricant without
- the invention also relates to the use of a chemical composition containing
- At least one polymeric guanidine biocide in aqueous solution at least one polymeric guanidine biocide in aqueous solution, and at least one vaginal thickener
- composition containing at least one polymeric guanidine biocide in aqueous solution, and at least one thickening agent in the sex organs involved in sexual intercourse,
- composition or any of its ingredients or application as defined above and below.
- the invention further relates to a method for
- a mechanical protection, such as a sponge or a barrier, by solid objects in the vagina are not required and can be omitted in the application according to the invention.
- composition of the invention is preferably a lubricating gel in the sense of a viscous liquid, wherein the
- a lubricant has the advantage of a pain-free and reduced-friction sexual intercourse. The occurring in women especially in the postmenopause
- Dryness of the vaginal mucosa is counteracted by the gel character of the formulation, which causes no pain in the sexual act or reduces its risk.
- a local anesthetic may be used as described above to counteract premature ejaculation of the male.
- composition according to the invention can be used both for
- composition of the invention may be employed or provided for use to reduce transmission of pathogens.
- pathogens may be bacteria, fungi or viruses.
- Bacteria, their transmission may be bacteria, fungi or viruses.
- inhibited according to the invention are e.g. S. aureus, E. coli, P. aeruginosa.
- Fungi whose transmission is inhibited according to the invention are e.g. C. albicans, S. cerevisiae.
- the polymeric guanidine shows strong virucidal activity.
- the literature describes the antiviral activity against classical viruses which are transmitted through sexual intercourse and against which it is to be protected, partly by testing with the structurally similar polymeric guanidine derivative polyhexamethylene biguanide (PHMB), see Romanowski et al. (JAMA Ophthalmol. 2013 Apr; 131 (4): 495-8), Gentile et al. (BMC Clinical Pathology 201212: 17), Valluri et al. (Cornea, 1997; 16 (5): 556-559), Passic et al. (Biomed
- Composition can be through the active ingredients and through the
- Gel / Acid / Polymer Blend reduce or prevent the transmission of virus from the virus carriers to the contact person's cells.
- Viruses whose transmission is reduced or prevented are, for example, HPV (human papillomavirus), HSV
- HIV human immunodeficiency virus
- the invention can be a targeted prevention of
- the formulations are based on biocidal active substances of the group of polyguanidines (Akacid, described in Kratzer et al., Antibiotika Monitor 1/2/2006, Buxbaum et al., Journal of
- polymeric guianidine compounds have an excellent antimicrobial profile and are also capable of stable
- Hexamethylenediamine and guanidine hydrochloride were prepared in a 1-step synthesis procedure and subsequently freed of low molecular weight and high molecular weight monomers by filtration through three NF membranes, resulting in a monomeric purified Akacid Plus fraction with better pharmacological properties.
- the average molecular weight of this Akacid Plus (or "X-Cid") is about 1000 daltons
- composition (mainly 500 to 3000 daltons).
- the composition was provided as an aqueous solution for further formulation.
- Active ingredient amounts are given in g or%. All% values are by weight unless otherwise stated.
- the formulation of the "Liquid Condom Female” consists of a hydroxyethyl cellulose-containing gel
- Hydroxyethylcellulose is swollen with Aqua Purificata for 5 minutes until a thin liquid gel has formed.
- the two active ingredients Akacid Plus 1000 in a concentration of 0.2-1%) and the spermicides active ingredient 9-nonoxinol (in a concentration of 5%) or other agents that promote contraception such as lactic acid,
- Citric acid, quinine, pomegranate seed extract, honey or crushed acacia sprouts are incorporated into the final gel base.
- the gel is administered via 1.8 ml disposable plastic pipettes, the head of which is to be unscrewed before use.
- the total amount is at least 1-3 minutes before To inject sexual intercourse intravaginally.
- the distribution of the gel is conditioned by the sexual act itself.
- Hydroxyethylcellulose-containing gel The hydroxyethylcellulose is swollen with Aqua Purificata for 5 minutes until a viscous gel is produced by rubbing.
- the two active ingredients Akacid Plus 1000 (for example, in a concentration of 0.2%) and the
- ointment base Incorporated ointment base.
- the local anesthetic is included for desensitization to counteract premature ejaculation.
- the pH is neutral to slightly basic.
- the formulation has no contraceptive effect and serves primarily against the infection of the man by an otherwise unprotected intercourse.
- the weighed Akacid Plus 1000 amount will be in the
- Nonoxinol-9 incorporated and after cooling to about 40 45 C ° poured into suppository molds 2g and allowed to cool until solidification.
- Example 5 Comparison of the antibacterial effect of the "liquid condom” compared to pure acacid
- Composition 1 "liquid condom” according to example 2 ("liquid condom female”); with nonoxinol-9
- Composition 2 "liquid condom” according to example 2 ("liquid condom female”) without nonoxinol-9 (instead of water)
- Composition 3 Akacid Plus, balance: water-tested pathogens:
- test compositions 50m ⁇ of the test compositions were added to the wells with the test compositions having different X-cid concentrations starting from 0.6%, 1: 1 dilutions each with the remaining compositional components, ie 0.6%, 0.3%, 0, 15%, 0.075%, 0.0375%, 0.0188%, 0.00938%, 0.00469%, 0.00234%, 0.00117% (rounded, all% in wt%).
- Pathogen samples were thawed and diluted in the respective medium. 50m1 of the challenge sample was then added to all wells (except negative control). The incubation was carried out overnight at 35.degree. The next day, the plates were visually evaluated and measured with the SpectraMax 190 Reader.
- MRSA had an activity of "liquid condoms" in all concentrations, and some outliers are due to the fact that possibly unequal amounts of substance are transported with the pipette, which may be possible because the substance itself was very viscous and therefore sometimes difficult to pipette exact quantities.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Urology & Nephrology (AREA)
- Agronomy & Crop Science (AREA)
- Dentistry (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18155747.1A EP3524055A1 (de) | 2018-02-08 | 2018-02-08 | Antibakterielles und spermizides gleitmittel |
PCT/EP2019/053127 WO2019154983A1 (de) | 2018-02-08 | 2019-02-08 | Antibakterielles und spermizides gleitmittel |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3749095A1 true EP3749095A1 (de) | 2020-12-16 |
Family
ID=61188675
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18155747.1A Withdrawn EP3524055A1 (de) | 2018-02-08 | 2018-02-08 | Antibakterielles und spermizides gleitmittel |
EP19702647.9A Withdrawn EP3749095A1 (de) | 2018-02-08 | 2019-02-08 | Antibakterielles und spermizides gleitmittel |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18155747.1A Withdrawn EP3524055A1 (de) | 2018-02-08 | 2018-02-08 | Antibakterielles und spermizides gleitmittel |
Country Status (9)
Country | Link |
---|---|
US (1) | US20210038637A1 (de) |
EP (2) | EP3524055A1 (de) |
JP (1) | JP2021513569A (de) |
KR (1) | KR20200119829A (de) |
CN (1) | CN111787802A (de) |
BR (1) | BR112020015955A2 (de) |
MX (1) | MX2020008140A (de) |
RU (1) | RU2020129407A (de) |
WO (1) | WO2019154983A1 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102022121008A1 (de) | 2022-08-19 | 2024-02-22 | pjur group Luxembourg S.A. | Wasserfreie silikonbasierte Gleitmittelzusammensetzung |
DE102022121007A1 (de) | 2022-08-19 | 2024-02-22 | pjur group Luxembourg S.A. | Wasserbasierte Gleitmittelzusammensetzung |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2325586A (en) | 1940-03-21 | 1943-08-03 | Du Pont | Polymeric guanidines and process for preparing the same |
BR6568736D0 (pt) | 1964-04-09 | 1973-08-14 | Drug Inc Sterling | Processo para preparar uma bisguanida |
US5182104A (en) * | 1991-07-16 | 1993-01-26 | Stanley Marcus | Topical virucidal composition for treatment of mucocutaneous tissue |
GR940100370A (el) | 1993-07-28 | 1994-07-26 | Johnson & Johnson Consumer Products Inc. | Μια σπερμοκτονος λιπαντικη αντι-ιου συνθεση και μεθοδος χρησης της. |
US6028115A (en) | 1995-10-13 | 2000-02-22 | Rush-Presbyterian-St. Luke's Medical Center | Method for preventing sexually transmitted diseases |
AT406163B (de) | 1998-04-22 | 2000-03-27 | P O C Oil Industry Technology | Verfahren zur gewinnung eines desinfektionsmittels |
CN1121855C (zh) * | 1999-04-28 | 2003-09-24 | 孙廷柱 | 可溶性杀菌消毒避孕套 |
AT408302B (de) | 2000-05-11 | 2001-10-25 | P O C Oil Industry Technology | Biozide polymere der reihe der polyoxyalkylen-guanidin-hydrochloride und verfahren zu deren herstellung |
AT411060B (de) | 2000-10-23 | 2003-09-25 | P O C Oil Industry Technology | Biozide polymere guanidinderivate auf der basis von diaminen und verfahren zur gewinnung von solchen salzen |
DE50104887D1 (de) | 2000-05-11 | 2005-01-27 | Poc Polymer Produktions Gmbh W | Biozide polymere auf der basis von guanidin-salzen |
WO2002030877A1 (fr) | 2000-09-29 | 2002-04-18 | Regionalnaya Obschestvennaya Organizatsya-Institut Ekologo-Tekhnologicheskikh Problem | Procede de production d'un desinfectant |
AT500998B1 (de) * | 2003-03-20 | 2008-10-15 | Geopharma Produktionsgmbh | Antimikrobiell wirkendes arzneimittel |
UA64406A (en) * | 2003-05-27 | 2004-02-16 | Neonila Havrylivna Barannik | Ointment for complex treatment of ulcerated necrotic gingivostomatitis |
AT505102B1 (de) | 2004-11-05 | 2010-05-15 | Schmidt Oskar | Biozid, insbesondere fungizid wirkendes mittel |
US7824383B2 (en) * | 2006-06-16 | 2010-11-02 | Family Health International | Vaginal drug delivery system and method |
WO2008031105A1 (en) * | 2006-09-08 | 2008-03-13 | Delaval Holdings Ab | Polymeric guanidine salt-based germicides |
US7897553B2 (en) * | 2006-10-23 | 2011-03-01 | Bausch & Lomb Incorporated | Biguanide composition with low terminal amine |
EP2071954A1 (de) * | 2007-12-19 | 2009-06-24 | Bayer CropScience AG | Verwendung von polymeren Guanidin-Derivaten zum Bekämpfen von unerwünschten Mikro-organismen im Pflanzenschutz |
US20100303752A1 (en) | 2006-12-29 | 2010-12-02 | Aka Technology Gmbh | Use of polymeric guanidines for controlling microorganisms |
AT505514B1 (de) | 2007-07-16 | 2011-10-15 | Aka Technology Gmbh | Silikatischer füllstoff |
EP2084967A1 (de) | 2008-01-24 | 2009-08-05 | Aka Central Research Laboratories GmbH | Verfahren zur Bekämpfung unerwünschter Mikroorganismen an Bananenpflanzen |
EP2230258A1 (de) | 2009-03-18 | 2010-09-22 | Mindinvest Holdings Ltd. | Mikrobiozid wirkendes Arzneimittel |
RU2422137C1 (ru) | 2009-10-08 | 2011-06-27 | Виктор Вениаминович Тец | Способ получения биоцидного полигуанидина и биоцидный полигуанидин |
WO2013064161A1 (de) | 2011-11-02 | 2013-05-10 | Mindinvest Holdings Ltd. | Polyguanidinsilikat und dessen verwendung |
US9386772B2 (en) * | 2012-02-14 | 2016-07-12 | Allegiance Corporation | Antimicrobial elastomeric articles |
AT513858B1 (de) | 2013-01-25 | 2014-08-15 | Sealife Pharma Gmbh | Neue bioaktive Polymere |
DE102014100274A1 (de) * | 2013-11-21 | 2015-05-21 | Farco-Pharma Gmbh | Zusammensetzung, insbesondere in Form eines Gels, sowie dessen Verwendung |
AT516070B1 (de) | 2014-07-31 | 2016-08-15 | Sealife Pharma Gmbh | Verfahren zur Herstellung von Polyguanidinen |
EP3167890A1 (de) * | 2015-11-12 | 2017-05-17 | Glock Health, Science and Research GmbH | Behandlung von vaginitis |
-
2018
- 2018-02-08 EP EP18155747.1A patent/EP3524055A1/de not_active Withdrawn
-
2019
- 2019-02-08 US US16/966,793 patent/US20210038637A1/en not_active Abandoned
- 2019-02-08 MX MX2020008140A patent/MX2020008140A/es unknown
- 2019-02-08 CN CN201980012288.5A patent/CN111787802A/zh active Pending
- 2019-02-08 JP JP2020565535A patent/JP2021513569A/ja active Pending
- 2019-02-08 BR BR112020015955-7A patent/BR112020015955A2/pt not_active Application Discontinuation
- 2019-02-08 WO PCT/EP2019/053127 patent/WO2019154983A1/de unknown
- 2019-02-08 EP EP19702647.9A patent/EP3749095A1/de not_active Withdrawn
- 2019-02-08 RU RU2020129407A patent/RU2020129407A/ru unknown
- 2019-02-08 KR KR1020207024818A patent/KR20200119829A/ko active Search and Examination
Also Published As
Publication number | Publication date |
---|---|
EP3524055A1 (de) | 2019-08-14 |
BR112020015955A2 (pt) | 2020-12-15 |
JP2021513569A (ja) | 2021-05-27 |
KR20200119829A (ko) | 2020-10-20 |
WO2019154983A1 (de) | 2019-08-15 |
CN111787802A (zh) | 2020-10-16 |
RU2020129407A (ru) | 2022-03-09 |
MX2020008140A (es) | 2020-10-12 |
US20210038637A1 (en) | 2021-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0700249B1 (de) | Antiinfektivum | |
DE69007547T2 (de) | Gepufferte Metronidazolmittel zur intravaginalen Behandlung vaginaler Infektionen. | |
DE69326824T2 (de) | Schnelltrocknendes gelartiges Desinfektionsmittel für Hände und Finger | |
DE69533724T2 (de) | Zusammensetzung zum inaktivieren von reizstoffen in flüssigkeiten | |
DE69419447T2 (de) | Salbe zur Wundbehandlung | |
DE3702983A1 (de) | Desinfektionsmittel und ihre verwendung zur haut- und schleimhautdesinfektion | |
DE69118081T2 (de) | Hyaluronsäurenatriumsalz und Desinfektionsmittel enthaltende pharmazeutische Zusammensetzungen zur äusserlichen Anwendung | |
DE202009019116U1 (de) | Wässrige pharmazeutische Zusammensetzungen, die Borat-Polyol-Komplexe enthalten | |
DD283932A5 (de) | Verfahren zur herstellung einer pharmazeutischen zusammensetzung zur verhuetung von sexuell uebertragbaren krankheiten | |
DE69224071T2 (de) | Chinolan-antibiotika und polystyrolsulfonat enthaltende zusammensetzungen | |
DE69511244T2 (de) | Haftende desinfizierende zusammensetzungen und verfahren und entsprechendes verfahren | |
EP3749095A1 (de) | Antibakterielles und spermizides gleitmittel | |
DE69526369T2 (de) | Entzündungshemmende augentropfen | |
DE69819900T2 (de) | Wässrige flüssige pharmazeutische zusammensetzung enthaltend ein benzopyranderivat als hauptbestandteil | |
AT500998B1 (de) | Antimikrobiell wirkendes arzneimittel | |
EP1196159B1 (de) | Verwendung von tosylchloramid(en) zur behandlung von erkrankungen der haut, der schleimhaut, von organen und geweben | |
EP1135116A1 (de) | Verwendung von poly (hexamethylen) biguanid zur herstellung eines mittels zur förderung der heilung von infektionsfreien wunden | |
WO2011100994A1 (de) | Arzneimittel enthaltend myramistin | |
DE69424793T2 (de) | Empfängnisverhütende zusammensetzungen | |
DE69634536T2 (de) | 2,4-dichlorbenzylalkohol und amylmetakresol gegen hiv-infektion | |
DE60223828T2 (de) | Spermizide | |
DE202012000247U1 (de) | Zusammensetzung für die topische Applikation II | |
EP3415163A1 (de) | Zusammensetzung mit lokalanästhetischer wirkung und deren verwendung | |
DE202017104675U1 (de) | Zusammensetzung mit lokalanästhetischer Wirkung und deren Verwendung | |
EP3400949B1 (de) | Zusammensetzung für die topische anwendung, insbesondere zur blaseninstillation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200817 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20210812 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20230901 |